• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan+
  • Wellness
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan+
  • Wellness
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Testosterone replacement in male cancer survivors helps improve body composition

byAlex ChanandRavi Shah, MD MBA
March 21, 2020
in Chronic Disease, Endocrinology, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Young male cancer survivors with low-normal serum morning total testosterone benefited from testosterone treatment as a therapeutic option to improve body composition.

Evidence Rating: 1 (Excellent)

Endocrine dysfunction as a long-term sequelae of cancer and its treatments affect are highly prevalent, affecting up to 50% of adult childhood cancer survivors. Impairment of the hypothalamic-pituitary-gonadal axis is one of particular concern, as evidence of impaired gonadal function is present in over 50% of male cancer survivors, manifesting as increased trunk mass, and worsened quality of life (QoL) in the 27% of young male cancer survivors aged 25-45 years that are below the 10th percentile of serum testosterone levels compared to matched controls. Previous research involving testosterone therapy tended to focus on older men over the age of 65, and the suitability of testosterone replacement as a therapeutic option to improve body composition and quality of life in childhood malignancy survivors had yet to be investigated. In this study, a total of 136 male survivors of testicular cancer, lymphoma, and leukemia aged 25-50 years (42.6% aged 25-37 years, 57.4% 38-50 years, 88% testicular cancer, 10% lymphoma, matched for body mass BMI) years with a morning total serum testosterone of 7-12nmol/l were randomized 1:1 between July 2012 and February 2015 to either receive testosterone (Tostran 2% gel) or placebo for 26 weeks. The coprimary end points were trunk fat mass and SF36 Physical Functioning score (SF36-PF) as a measure of QoL at 26 weeks by intention to treat. Compared to placebo, the treatment group receiving testosterone had significantly decreased trunk fat mass (-0.9kg, 95% CI -1.6 to -0.3, p = 0.0073), decreased whole-body fat mass (-1.8kg, 95% CI -2.9 to -0.7, p = 0.0016), and increased lean body mass (1.5kg, 95% CI 0.9-2.1, p < 0.001). There was no associated change in QoL or metabolic profile, and the treatment was generally well tolerated. Study findings demonstrate that testosterone replacement improves body composition in young male cancer survivors, and may be considered in the context of other interventions to reduce trunk mass and increase muscle mass.

Click to read the study in PLOS Medicine

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

CAR+ T-cell lymphoma linked to cilta-cel therapy in myeloma

Nivolumab+AVD improves progression-free survival in advanced-stage Hodgkin lymphoma

Nivolumab+AVD Improves Survival in Advanced Classic Hodgkin’s Lymphoma Compared to Brentuximab Vedotin+AVD

Tags: hypothalamic-pituitary-gonadal axislymphomaTesticular CancertestosteroneTostran
Previous Post

Large study describes characteristics of children with COVID-19 in China

Next Post

#VisualAbstract: The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases

RelatedReports

Chemotherapy and stem-cell transplant for multiple myeloma remain superior
Hematology

CAR+ T-cell lymphoma linked to cilta-cel therapy in myeloma

March 7, 2025
Adaptive interim PET-CT guides treatment for advanced Hodgkin’s lymphoma
Chronic Disease

Nivolumab+AVD improves progression-free survival in advanced-stage Hodgkin lymphoma

November 21, 2024
Nivolumab+AVD Improves Survival in  Advanced Classic Hodgkin’s Lymphoma Compared to Brentuximab Vedotin+AVD
StudyGraphics

Nivolumab+AVD Improves Survival in Advanced Classic Hodgkin’s Lymphoma Compared to Brentuximab Vedotin+AVD

October 30, 2024
Niraparib may lengthen progression-free survival for patients with recurrent ovarian cancer
Chronic Disease

Brentuximab-based chemotherapy improves survival and reduces toxicity in patients with advanced Hodgkin lymphoma

August 28, 2024
Next Post
#VisualAbstract: The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases

#VisualAbstract: The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases

MMF and rituximab combination effective in nephrotic syndrome

SARS-CoV-2 detected in respiratory, fecal, and serum specimens

Fish oil supplementation likely reduces cardiovascular morbidity and mortality

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Particulate foods not associated with incident diverticulitis in women
  • Patients with varicose veins may be at an increased risk of dementia
  • Substantial thyroid disease reclassification under demographic-specific thyroid function reference intervals
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.